Overview
Health care cost to society has risen to levels which are no longer sustainable.
This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology.
The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in “pure-play” digital health companies, which are typically small to mid-sized.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry.
The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.
Risks
Features
| Product category |
麻豆社 Thematic Funds
|
| Product domicile |
Luxembourg
|
| Portfolio management |
麻豆社 Asset Management (Americas) LLC, New York
|
| Fund management |
麻豆社 Asset Management (Europe) S.A., Luxembourg
|
| Custodian bank |
麻豆社 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
麻豆社 Asset Management (UK) Limited
|
| Day of inception |
14 December 2017
|
| Currency of account |
CHF
|
| Close of financial year |
31 May
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.05% p.a.
|
| Management fee |
0.78% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI AC World (NR) (CHF hedged)
|
| ISIN |
LU1683288697
|
| Bloomberg Ticker |
CSGDUBH LX
|
| Reuters Id |
38312206X.CHE
|
Performance and Prices
Percentage growth
as of 18 June 2026| CHF(%) | EUR(%) | |
| YTD | ||
| 1M | ||
| 3M | 2.82 | 1.39 |
| 6M | -7.40 | -6.42 |
| 1Y | 0.32 | 2.47 |
| 2Y | -1.68 | 1.36 |
| 3Y | -20.37 | -15.60 |
| 5Y | ||
| ø p.a.5Y | -14.54 | -11.56 |
| CHF(%) | EUR(%) | |
| Q1 2025 to Q1 2026 | 1.82 | 5.10 |
| Q1 2024 to Q1 2025 | -17.44 | -15.97 |
| Q1 2023 to Q1 2024 | 0.06 | 2.09 |
| Q1 2022 to Q1 2023 | -21.16 | -18.67 |
| Q1 2021 to Q1 2022 | -31.27 | -25.75 |
Current data
| Net asset value | 18.06.2026 | CHF 107.82 |
| High - last 12 months | 07.01.2026 | CHF 122.85 |
| Low - last 12 months | 18.05.2026 | CHF 99.12 |
| Assets of the unit class in mn | 17.06.2026 | CHF 15.61 |
| Total product assets in mn | 17.06.2026 | CHF 350.41 |
Structures
By the 10 largest positions (in %, as of 29 May 2026)
|
|
|
| Guardant Health Inc | 4.27 |
| Intuitive Surgical Inc | 3.14 |
| Arrowhead Pharmaceuticals Inc | 3.05 |
| Koninklijke Philips NV | 2.86 |
| IRhythm Holdings Inc | 2.81 |
| Natera Inc | 2.73 |
| Ionis Pharmaceuticals Inc | 2.71 |
| Alcon AG | 2.71 |
| Denali Therapeutics Inc | 2.70 |
| Dexcom Inc | 2.69 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
| Prospectus |
|
| Country supplement |
|
| Key Investor Information (KIID) |
|
| Past performance |
|
| Previous performance scenario |
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|